Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458495 | 1.00 | HTR2A (0.35) | HTR2AHTR2CHTR2BOPRM1PDPK1 | |
| SCHEMBL6521360 | 1.00 | HTR2A (0.35) | HTR2AHTR2CHTR2BOPRM1PDPK1 | |
| SCHEMBL3389204 | 0.77 | HTR2A (0.35) | HTR2AHTR2CPDPK1HRH1 | |
| SCHEMBL8890669 | 0.76 | CHRNB2 (0.33) | HTR2AOPRM1PDPK1 | |
| SCHEMBL4307808 | 0.75 | HTR2A (0.34) | HTR2AHTR2CHRH1 | |
| SCHEMBL874497 | 0.75 | HTR2A (0.34) | HTR2AHTR2CHRH1 | |
| SCHEMBL455932 | 0.75 | HTR2A (0.34) | HTR2AHTR2COPRM1HRH1 | |
| SCHEMBL458123 | 0.75 | HTR2A (0.34) | HTR2AHTR2CHRH1 | |
| SCHEMBL7883084 | 0.75 | HTR2A (0.37) | HTR2AHTR2CHTR2BHRH1 | |
| SCHEMBL8679592 | 0.75 | HTR2A (0.37) | HTR2AHTR2CHTR2BHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101525-A1 | METHOD OF COMPLEXING A NUCLEIC ACID WITH A LIPID-CONJUGATED POLYAMIDE | ZUCKERMANN RONALD N (US) | 2005-05-12 | — | — | US | claimed |
| EP-1003558-B1 | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | CHIRON CORP (US) | 2004-03-17 | — | — | EP | claimed |
| US-20040018962-A1 | Lipid-conjugated polyamide compounds | CHIRON CORPORATION | 2004-01-29 | — | — | US | claimed |
| US-6572881-B1 | Delivery of polynucleotides to cells; polylactam | CHIRON CORPORATION | 2003-06-03 | — | — | US | claimed |
| US-6569450-B1 | For facilitating the delivery of polynucleotides to cells | CHIRON CORPORATION | 2003-05-27 | — | — | US | claimed |
| US-6197332-B1 | ACYLATION AND AMIDATION TO FORM POLYAMIDES FOR CONJUGATED LIPIDS | CHIRON CORPORATION | 2001-03-06 | — | — | US | claimed |
| EP-1003558-A1 | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | CHIRON CORPORATION (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999008711-A1 | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | CHIRON CORPORATION (US) | 1999-02-25 | — | — | WO | claimed |
| US-20150031743-A1 | CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA, RELATED COMPOSITIONS AND METHODS OF MAKING AND USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8772255-B2 | Cell transfecting formulations of small interfering RNA related compositions and methods of making and use | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-1709195-B1 | CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA, RELATED COMPOSITIONS AND METHODS OF MAKING AND USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20090143322-A1 | CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA RELATED COMPOSITIONS AND METHODS OF MAKING AND USE | CHIRON CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| US-7214384-B2 | Lipid-conjugated polyamide compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060019912-A1 | Cell transfecting formulations of small interfering RNA related compositions and methods of making and use | CHIRON CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20040018962-A1 | Lipid-conjugated polyamide compounds | CHIRON CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6572881-B1 | Delivery of polynucleotides to cells; polylactam | CHIRON CORPORATION | 2003-06-03 | — | — | US | disclosed |
| US-6569450-B1 | For facilitating the delivery of polynucleotides to cells | CHIRON CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-6197332-B1 | ACYLATION AND AMIDATION TO FORM POLYAMIDES FOR CONJUGATED LIPIDS | CHIRON CORPORATION | 2001-03-06 | — | — | US | disclosed |
| EP-1003558-A1 | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | CHIRON CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999008711-A1 | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | CHIRON CORPORATION (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019912-A1 | Cell transfecting formulations of small interfering RNA related compositions and methods of making and use | SNRPE, SNRPA, PHAX | HTR2A 4604/4885HTR2C 4789/4885HTR2B 4671/4885 |
| US-20090143322-A1 | CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA RELATED COMPOSITIONS AND METHODS OF MAKING AND USE | SNRPE, SNRPA, PHAX | HTR2A 4604/4885HTR2C 4789/4885HTR2B 4671/4885 |
| US-20150031743-A1 | CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA, RELATED COMPOSITIONS AND METHODS OF MAKING AND USE | SNRPE, PHAX, SNRPA | HTR2A 4493/4885HTR2C 4764/4885HTR2B 4654/4885 |
| US-20040018962-A1 | Lipid-conjugated polyamide compounds | LPCAT3, PHOSPHO1, LPCAT1 | HTR2A 4680/4885HTR2C 4832/4885HTR2B 4827/4885 |
| US-20050101525-A1 | METHOD OF COMPLEXING A NUCLEIC ACID WITH A LIPID-CONJUGATED POLYAMIDE | POLRMT, POLI, LPCAT3 | HTR2A 4598/4885HTR2C 4828/4885HTR2B 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.